{"version":"1.0","provider_name":"Kompetenznetz Multiple Sklerose","provider_url":"https:\/\/kknms.woomera.de\/en\/","author_name":"Zo\u00eb Hunter","author_url":"https:\/\/kknms.woomera.de\/en\/author\/kknms-hunter\/","title":"Neues Qualit\u00e4tshandbuch online verf\u00fcgbar: Satralizumab - Kompetenznetz Multiple Sklerose","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"zJD6sjIgk9\"><a href=\"https:\/\/kknms.woomera.de\/en\/neues-qualitaetshandbuch-online-verfuegbar-satralizumab\/\">Neues Qualit\u00e4tshandbuch online verf\u00fcgbar: Satralizumab<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/kknms.woomera.de\/en\/neues-qualitaetshandbuch-online-verfuegbar-satralizumab\/embed\/#?secret=zJD6sjIgk9\" width=\"600\" height=\"338\" title=\"&#8220;Neues Qualit\u00e4tshandbuch online verf\u00fcgbar: Satralizumab&#8221; &#8212; Kompetenznetz Multiple Sklerose\" data-secret=\"zJD6sjIgk9\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/kknms.woomera.de\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"10.12.2021 \u2013\u00a0Das Krankheitsbezogene Kompetenznetz Multiple Sklerose (KKNMS) in Zusammenarbeit mit der der Neuromyelitis Optica Studiengruppe (NEMOS) und der Deutsche Multiple Sklerose Gesellschaft (DMSG) stellen das neue Kapitel des Qualit\u00e4tshandbuchs zu dem NMOSD-Medikament\u00a0Satralizumab\u00a0vor.\u00a0 Das Qualit\u00e4tshandbuch des KKNMS ist eine Handreichung f\u00fcr \u00c4rzte, die MS- \/ NMOSD-Patienten behandeln. Satralizumab ist ein humanisierter monoklonaler anti-Interleukin-6 (IL-6) Rezeptor-Antik\u00f6rper und [&hellip;]"}